Phase III results in Genotype 1 naïve patients: Predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin

Liver International

Volumn 32, Issue SUPPL. 1, 2012, Pages 39-43

  Kwo, Paul Y ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Direct acting antiviral; IL28B; Personalized medicine; Viral kinetics

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON PLUS RIBAVIRIN; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ADD ON THERAPY; BODY MASS; DISEASE COURSE; DRUG RESPONSE; GENOTYPE; GENOTYPE 1 HEPATITIS C; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDIANA; INTERFERON-ALPHA; INTERLEUKINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SERINE PROTEINASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84855245619     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02709.x     Document Type: Review

References (14)

1. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
3. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
4. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-71.
5. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in Genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9. e18.
6. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with specific genotypes, viral replication, and liver fibrosis. Gastroenterology, 2008; 134: 416-23.
7. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance. Nature 2009; 461: 391-401.
8. Asselah T. Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. J Hepatol 2010; 52: 452-4.
9. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
10. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011; 54: S542-3.
11. Sulkowski MS, Reddy R, Afdhal NH, et al. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies. J Hepatol 2011; 54: S195.
12. Brass C, Barnard RJO, Howe JA, et al. Sustained virologic response and boceprevir resistance-associated variants observed in patients infected with HCV genotype 1a/1b when treated with boceprevir plus peg interferon alfa-2b/ribavirin. J Hepatol 2011;54(Suppl. 1):S471-2.
13. Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with bocepreivr (BOC) combination therapy. J Hepatol 2011; 54: S6.
14. Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates. Analysis of previously untreated and previously treatment-failure patients. J Hepatol 2011; 54: S194-5.